Patents by Inventor Uday Khire

Uday Khire has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100125139
    Abstract: A process for the preparation of various quinazoline compounds which are useful as Rho-Kinase inhibitors, and thus having utility in the treatment of hypertension and other indications.
    Type: Application
    Filed: November 17, 2009
    Publication date: May 20, 2010
    Inventors: Donald BANKSTON, Dhanaphalan Nagarathnam, Davoud Asgari, Jianxing Shao, Xiao-Gao Liu, Uday Khire, Chunguang Wang, Barry Hart, Stephen Boyer, Olaf Weber, Mark Lynch
  • Publication number: 20100063038
    Abstract: This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 1, 2006
    Publication date: March 11, 2010
    Inventors: Julie Dixon, Barton Phillips, Furahi Achebe, Harold Kluender, Jason Newcom, Kyle Parcella, Stephen J. O'Connor, Steven Magnuson, Zhenqui Hong, Zhonghua Zhang, Zheng Liu, Uday Khire, Lei Wang, Martin Michels, Brent Chandler
  • Patent number: 7648986
    Abstract: Disclosed are compounds and derivatives thereof their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.
    Type: Grant
    Filed: April 9, 2007
    Date of Patent: January 19, 2010
    Assignee: Bayer Healthcare LLC
    Inventors: Dhanapalan Nagarathnam, Uday Khire, Davoud Asgari, Jianxing Shao, Xiao-Gao Liu, Chunguang Wang, Barry Hart, Olaf Weber, Mark Lynch, Lei Zhang, Lei Wang
  • Patent number: 7645878
    Abstract: A process for the preparation of various quinazoline compounds which are useful as Rho-Kinase inhibitors, and thus having utility in the treatment of hypertension and other indications.
    Type: Grant
    Filed: September 24, 2002
    Date of Patent: January 12, 2010
    Assignee: Bayer Healthcare LLC
    Inventors: Donald Bankston, Dhanaphalan Nagarathnam, Davoud Asgari, Jianxing Shao, Xiao-Gao Liu, Uday Khire, Chunguang Wang, Barry Hart, Stephen Boyer, Olaf Weber, Mark Lynch
  • Patent number: 7625915
    Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: December 1, 2009
    Assignee: Bayer HealthCare LLC
    Inventors: Jacques Dumas, Uday Khire, Timothy B. Lowinger, Bernard Riedl, William J. Scott, Roger A. Smith, Jill E. Wood, Holia Hatoum-Mokdad, Jeffrey Johnson, Aniko Redman, Robert Sibley
  • Publication number: 20090118268
    Abstract: This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: October 10, 2008
    Publication date: May 7, 2009
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert N. Sibley
  • Patent number: 7528255
    Abstract: The invention relates to the use of a group of aryl ureas in treating raf mediated diseases and pharmaceutical compositions for use in such therapy of the formula wherein, Y is NHR Hal is chlorine or bromine, R is H, CH3 or CH2OH, and X1 to X7 are each, independently, H, OH or —OC(O)C1-C4 alkyl, or a salt purified stereoisomer thereof, wherein at least one of X1 to X7 is OH or —OC(O)C1-C4 alkyl.
    Type: Grant
    Filed: February 11, 2002
    Date of Patent: May 5, 2009
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy Lowinger, William Scott, Roger Smith, Jill Wood
  • Patent number: 7517880
    Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: April 14, 2009
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Scott Miller, Martin Osterhout, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, David E. Gunn, Holia Hatoum-Mokdad, Marell Rodriguez, Robert Sibley, Ming Wang, Tiffany Turner, Catherine Brennan
  • Publication number: 20090093526
    Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: October 31, 2007
    Publication date: April 9, 2009
    Inventors: Scott Miller, Martin Osterhout, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, David E. Gunn, Holia Hatoum-Mokdad, Marell Rodriguez, Robert Sibley, Ming Wang, Tiffany Turner, Catherine Brennan
  • Publication number: 20080300281
    Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: July 28, 2008
    Publication date: December 4, 2008
    Inventors: Jacques Dumas, Uday Khire, Timothy B. Lowinger, Bernd Riedl, William J. Scott, Roger A. Smith, Jill E. Wood, Holia Hatoum-Mokdad, Jeffrey Johnson, Aniko Redman, Robert Sibley
  • Publication number: 20080293696
    Abstract: A compound having the formula (1) in which the ring containing E is a phenyl, a pyridine, or a pyrimidine. In formula (1) the symbol A represents wherein the group R4 represents halogen, CF3, or H, provided that the maximum number of CF3 groups on any A is 2, and the maximum number of hydrogens on A is 2 for the A groups which together with the carbon atoms to which they are attached form 6-membered rings, and the maximum number of hydrogens on A is 1 for the A group which together with the carbon atoms to which it is attached forms a 5-membered ring. Z represents N or CH when E forms a phenyl ring, and represents CH when E forms a pyridine or pyrimidine. The groups R1, R2 and R3 and the subscripts a, b, and d are as defined in the text and claims. Pharmaceutical compositions containing a compound of formula (1) and methods of treating cancer using compounds of formula (1) are also disclosed and claimed.
    Type: Application
    Filed: June 23, 2005
    Publication date: November 27, 2008
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Catherine Brennan, Julie A. Dixon, William J. Scott, Aniko Redman, Benjamin D. Jones, Barton Phillips, Philip Wickens, Istvan Enyedy, Ellalahewage Kumarasinghe, Charles Kreiman, Jacques Dumas, Uday Khire, Chih-Yuan Chuang, Harold C.E. Kluender, Zhenqiu Hong, Lei Wang, Donald Bierer
  • Publication number: 20080269265
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: June 25, 2008
    Publication date: October 30, 2008
    Inventors: Scott Miller, Martin Osterhout, Jacques Dumas, Uday Khire, Timothy B. Lowinger, Bernd Riedl, William J. Scott, Roger A. Smith, Jill E. Wood, David Gunn, Martha Rodriguez, Ming Wang, Tiffany Turner, Catherine Brennan
  • Publication number: 20080194580
    Abstract: This invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.
    Type: Application
    Filed: October 31, 2007
    Publication date: August 14, 2008
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Robert N. Sibley, Holia Hatoum-Mokdad, Mary-Katherine Monahan, David E. Gunn, Timotthy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood
  • Publication number: 20080153823
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: December 13, 2007
    Publication date: June 26, 2008
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert Sibley
  • Patent number: 7371763
    Abstract: The invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: May 13, 2008
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Robert N. Sibley, Holia Hatoum-Mokdad, Mary-Katherine Monahan, David E. Gunn, Timotthy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood
  • Publication number: 20080108672
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: June 25, 2007
    Publication date: May 8, 2008
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert N. Sibley
  • Patent number: 7351834
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Grant
    Filed: January 12, 2000
    Date of Patent: April 1, 2008
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy Lowinger, William Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert Sibley
  • Patent number: 7329670
    Abstract: The compounds are aryl and heteroaryl substituted heterocyclic ureas of the formula A—NH—C(O)—NH—B where A is the aryl or hetaryl substituted heterocyclic group and B is an aryl or heteroaryl moiety. The compounds inhibit raf kinase and are useful in the treatment of RAF kinase mediated diseases.
    Type: Grant
    Filed: December 27, 1999
    Date of Patent: February 12, 2008
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Jacques Dumas, Uday Khire, Timothy B. Lowinger, Bernard Riedl, William J. Scott, Roger A. Smith, Jill E. Wood, Holia Hatoum-Mokdad, Jeffrey Johnson, Aniko Redman, Robert Sibley
  • Publication number: 20080032979
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: August 27, 2007
    Publication date: February 7, 2008
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy Lowinger, Scott William, Roger Smith, Jill Wood, Mary-Katherine Monahan, Reink Natero, Joel Renick, Robert Sibley
  • Publication number: 20080027061
    Abstract: This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: August 27, 2007
    Publication date: January 31, 2008
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy Lowinger, William Scott, Roger Smith, Jill Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert Sibley